ArticleScientific reports2019
Risk of End-Stage Renal Disease in Psoriatic Patients: Real-World Data from a Nationwide Population-Based Cohort Study.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association of psoriasis with chronic kidney disease and end-stage renal disease: a systematic review and meta-analysis.Frontiers in medicine · 2023Pooled it
- Envudeucitinib, a Potent, Next-Generation, Allosteric Inhibitor of TYK2: A Narrative Review.Dermatology and therapy · 2026Review
- Prospective Pilot Study of Lavender Terpenoid Topical Formulation in Psoriasis Patients with Chronic Kidney Disease: Clinical and Inflammatory Outcomes.Biomedicines · 2026Article
- Ultrasound Renal Stress Test Assessment in Moderate-to-Severe Psoriasis: A Pilot Study.Psoriasis (Auckland, N.Z.) · 2026Article
- Cardiovascular and Kidney Outcomes After Systemic Treatment for Plaque Psoriasis: A Systematic Review and Network Meta-analysis.Dermatology and therapy · 2025Article
- Transcriptome dissection reveals the molecular basis of systemic associations in psoriasis.Archives of dermatological research · 2025Article
- Successful Treatment with Secukinumab in a Psoriasis Patient on Hemodialysis.Psoriasis (Auckland, N.Z.) · 2025Article
- Observational
- Association between Psoriasis and Renal Functions: An Integration Study of Observational Study and Mendelian Randomization.Biomedicines · 2024Article
- Review
- Case-Fatality and Temporal Trends in Patients with Psoriasis and End-Stage Renal Disease.Journal of clinical medicine · 2022Article
- Psoriasis and Systemic Inflammatory Disorders.International journal of molecular sciences · 2022Review
- Psoriatic Arthritis: The Influence of Co-morbidities on Drug Choice.Rheumatology and therapy · 2022Review
- Serum Intestinal Metabolites are Raised in Patients with Psoriasis and Metabolic Syndrome.Clinical, cosmetic and investigational dermatology · 2022Article
- Psoriasis and Renal Disorders: A Large-Scale Population-Based Study in Children and Adults.Dermatology (Basel, Switzerland) · 2022Article
- Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review.Frontiers in immunology · 2022Review
- Low hemoglobin levels and an increased risk of psoriasis in patients with chronic kidney disease.Scientific reports · 2021Article
- Proteinuria and Psoriasis Risk: A Nationwide Population-Based Study.Journal of clinical medicine · 2021Article
- The Th17/IL-17 Axis and Kidney Diseases, With Focus on Lupus Nephritis.Frontiers in medicine · 2021Review
- Current understanding and future perspectives of brain-heart-kidney axis in psoriatic arthritis.Rheumatology international · 2020Review
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic inflammatory skin disorder mediated by the T-cell-related immune response. Psoriatic patients may have a variety of comorbidities, but their risk of end-stage renal disease (ESRD), particularly according to the subtype of psoriasis, is unclear. We investigated the risk of ESRD in patients with psoriasis according to the subtype of psoriasis and history of systemic therapy for psoriasis. A total of 2,121,228 adults (1,590,921 in the control group and 530,307 in the psoriasis group) were enrolled in this nationwide population-based cohort study until 2015. During follow-up, 1,434 of the subjects in the psoriasis group developed ESRD. After adjusting for confounding factors, psoriasis was associated with the risk of ESRD (hazard ratio (HR) 1.58, 95% confidence interval [95% CI] 1.47-1.68). The psoriatic arthritis group (HR 7.60, 95% CI 1.90-30.41) had a higher risk of ESRD than the control group. Interestingly, no such association was detected in the systemically treated group (HR 1.07, 95% CI 0.80-1.41). Moreover, the acitretin-treated group had a lower risk of ESRD (HR 0.658, 95% CI, 0.494-0.875) than the non-systemically treated group. In conclusion, the risk of developing ESRD in patients with psoriasis differed according to the type of treatment and the presence of arthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.